Use of Cangrelor in Cervical and Intracranial Stenting for the Treatment of Acute Ischemic Stroke: A “Real Life” Single-Center Experience

References

1. 1.↵
   1. Powers WJ,
   2. Rabinstein AA,
   3. Ackerson T, et al

   ; American Heart Association Stroke Council. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2018;49:e46–110 doi:10.1161/STR.0000000000000158 pmid:29367334

   Abstract/FREE Full Text
2. 2.↵
   1. Grigoryan M,
   2. Haussen DC,
   3. Hassan AE, et al

   . Endovascular treatment of acute ischemic stroke due to tandem occlusions: large multicenter series and systematic review. Cerebrovasc Dis 2016;41:306–12 doi:10.1159/000444069 pmid:26881779

   CrossRefPubMed
3. 3.↵
   1. Holmstedt CA,
   2. Turan TN,
   3. Chimowitz MI

   . Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol 2013;12:1106–14 doi:10.1016/S1474-4422(13)70195-9 pmid:24135208

   CrossRefPubMed
4. 4.↵
   1. Windecker S,
   2. Meier B

   . Late coronary stent thrombosis. Circulation 2007;116:1952–65 doi:10.1161/CIRCULATIONAHA.106.683995 pmid:17965406

   FREE Full Text
5. 5.↵
   1. Farrokh S,
   2. Owusu K,
   3. Lara LR, et al

   . Neuro-interventional use of oral antiplatelets: a survey of neuro-endovascular centers in the United States and review of the literature. J Pharm Pract 2019 Jul 21. [Epub ahead of print] doi:10.1177/0897190019854868 pmid:31327286

   CrossRefPubMed
6. 6.↵
   1. Zhu F,
   2. Anadani M,
   3. Labreuche J, et al

   ; TITAN Investigators. Impact of antiplatelet therapy during endovascular therapy for tandem occlusions: a collaborative pooled analysis. Stroke 2020;51:1522–29 doi:10.1161/STROKEAHA.119.028231 pmid:32188367

   CrossRefPubMed
7. 7.↵
   1. Valgimigli M,
   2. Bueno H,
   3. Byrne RA, et al

   ; ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–60 doi:10.1093/eurheartj/ehx419 pmid:28886622

   CrossRefPubMed
8. 8.↵
   R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2019. https://www.R-project.org/. Accessed May 5, 2020
9. 9.↵
   1. Al-Mufti F,
   2. Amuluru K,
   3. Manning NW, et al

   . Emergent carotid stenting and intra-arterial abciximab in acute ischemic stroke due to tandem occlusion. Br J Neurosurg 2017;31:573–79 doi:10.1080/02688697.2017.1297377 pmid:28298139

   CrossRefPubMed
10. 10.↵
    1. Pan X,
    2. Zheng D,
    3. Zheng Y, et al

    . Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke. Eur J Neurol 2019;26:1105–10 doi:10.1111/ene.13946 pmid:30793464

    CrossRefPubMed
11. 11.↵
    1. Aguilar-Salinas P,
    2. Agnoletto GJ,
    3. Brasiliense LBC, et al

    . Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study. J Neurointerv Surg 2019;11:347–51 doi:10.1136/neurintsurg-2018-014396

    Abstract/FREE Full Text
12. 12.↵
    1. Linfante I,
    2. Ravipati K,
    3. Starosciak AK, et al

    . Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention. J Neurointerv Surg 2000 May 15. [Epub ahead of print] doi:10.1136/neurintsurg-2020-015841 pmid:32414891

    Abstract/FREE Full Text
13. 13.↵
    1. Elhorany M,
    2. Lenck S,
    3. Degos V, et al

    . Cangrelor and stenting in acute ischemic stroke: monocentric case series. Clin Neuroradiol 2020 May 7. [Epub ahead of print] doi:10.1007/s00062-020-00907-0 pmid:32382875

    CrossRefPubMed
14. 14.↵
    1. Abdennour L,
    2. Sourour N,
    3. Drir M, et al

    . Preliminary experience with cangrelor for endovascular treatment of challenging intracranial aneurysms. Clin Neuroradiol 2019 Jul 15. [Epub ahead of print] doi:10.1007/s00062-019-00811-2 pmid:31309241

    CrossRefPubMed
15. 15.↵
    1. Storey RF,
    2. Sanderson HM,
    3. White AE, et al

    . The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925–34 doi:10.1046/j.1365-2141.2000.02208.x pmid:11054084

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Bhatt DL,
    2. Stone GW,
    3. Mahaffey KW, et al

    ; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303–13 doi:10.1056/NEJMoa1300815 pmid:23473369

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Lipinski MJ,
    2. Lee RC,
    3. Gaglia MA, et al

    . Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: a network meta-analysis. Cardiovasc Revasc Med 2016;17:535–45 doi:10.1016/j.carrev.2016.09.011 pmid:27842901

    CrossRefPubMed
18. 18.↵
    1. Bhattad VB,
    2. Gaddam S,
    3. Lassiter MA, et al

    . Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med 2019;7:408 doi:10.21037/atm.2019.07.64 pmid:31660307

    CrossRefPubMed
19. 19.↵
    1. Godier A,
    2. Mesnil M,
    3. De Mesmay M, et al

    . Bridging antiplatelet therapy with cangrelor in patients with recent intracranial stenting undergoing invasive procedures: a prospective case series. Br J Anaesth 2019;123:e2–e5 doi:10.1016/j.bja.2019.03.019 pmid:31010645

    CrossRefPubMed
20. 20.↵
    1. Van Tuyl JS,
    2. Newsome AS,
    3. Hollis IB

    . Perioperative bridging with glycoprotein IIb/IIIa inhibitors versus cangrelor: balancing efficacy and safety. Ann Pharmacother 2019;53:726–37 doi:10.1177/1060028018824640 pmid:30646761

    CrossRefPubMed
21. 21.↵
    1. Neumann FJ,
    2. Hochholzer W,
    3. Pogatsa-Murray G, et al

    . Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001;37:1323–28 doi:10.1016/s0735-1097(01)01165-2 pmid:11300442

    FREE Full Text
22. 22.↵
    1. Schneider DJ,
    2. Agarwal Z,
    3. Seecheran N, et al

    . Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv 2014;7:435– 42 doi:10.1016/j.jcin.2013.08.017 pmid:24656538

    Abstract/FREE Full Text
23. 23.↵
    1. Steinhubl SR,
    2. Oh JJ,
    3. Oestreich JH, et al

    . Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008;121:527–34 doi:10.1016/j.thromres.2007.05.020 pmid:17631948

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Dovlatova NL,
    2. Jakubowski JA,
    3. Sugidachi A, et al

    . The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008;6:1153–59 doi:10.1111/j.1538-7836.2008.03020.x pmid:18485086

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Farooq MU,
    2. Goshgarian C,
    3. Min J, et al

    . Pathophysiology and management of reperfusion injury and hyperperfusion syndrome after carotid endarterectomy and carotid artery stenting. Exp Transl Stroke Med 2016;8:7 doi:10.1186/s13231-016-0021-2 pmid:27602202

    CrossRefPubMed